Medical Devices. Driving Growth With Transformational Technology

Transcription

1 Medical Devices Driving Growth With Transformational Technology

2 Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of Abbott cautions that these forwardlooking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott s operations are discussed in Item 1A, Risk Factors, to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2013, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 2 Page 2

3 Balanced and Diverse Medical Device Business Abbott Medical Devices: $5.5Bn Vascular: $3.01Bn Coronary portfolio (DES/BVS) Structural heart Endovascular Diabetes: $1.3B Diabetes: $1.31Bn Blood glucose meters Blood glucose strips Medical Optics: $1.1B Vision Care: $1.14Bn Cataract >65% of Vision Care sales Refractive Corneal solutions 3 Page 3

4 Large Market Aligned with Healthcare Trends Emerging Market Investments in Healthcare Aging Population Incidence of Chronic Diseases Need for Value-Creating Healthcare Solutions $30 Billion Medical Device Market 4 Page 4

5 Leadership Positions Across Medical Devices Vascular #1 Coronary Stents #1 Bioresorbable Vascular Scaffold (BVS) #1 Mitral Valve Repair Device Diabetes #2 in U.S. retail New Flash Glucose Monitoring technology in development Vision Care #1 LASIK #2 Cataract 5 Page 5

6 Innovation Driving Profitable Growth Vascular Diabetes Care Vision Care Near-term Xience Xpedition DES FreeStyle InsuLinx Tecnis Mono/Multifocal Absorb BVS FreeStyle Precision Neo Tecnis Toric; Optiblue MitraClip FreeStyle Precision Pro Pre-loaded delivery system Supera Peripheral Stent OptiMedica Catalys laser cataract system Mid-term Absorb BVS - Japan, U.S., and China Flash Glucose Monitoring technology Refresh refractive portfolio with idesign 6 Page 6

7 Growing Presence in Emerging Markets 24% Vascular Growing to low 30s as % of sales 17% Diabetes Growing to low 20s as % of sales 20% Vision Care Growing to mid 20s as % of sales 7 Page 7

8 Vascular Growth Strategies New Technology Expansion and Emerging Market Growth Coronary Continue to expand Absorb and Xpedition usage Structural Heart Drive adoption of MitraClip Endovascular Supera Peripheral Stent System Expand globally into new markets 8 Page 8

9 Absorb: the 4th Revolution Today 1977 Balloon Angioplasty (PTCA) Bare Metal Stents (BMS) Coronary Drug Eluting Stents (DES) Absorb Bioresorbable Vascular Scaffold (BVS) After implant. After resorption. 9 Page 9

10 Absorb: Expanding Global BVS Leadership Near-Term Growth Opportunity Available in more than 60 countries worldwide Supported by a robust clinical trial program More than 5,000 patients enrolled in company-sponsored trials Completed enrollment in Absorb randomized controlled trials in U.S., Japan, and China Combined, these markets account for more than 50 percent of the global heart stent market 10 Page 10

11 Mitral Valve Disease Large Patient Population; Significant Need Prevalence of Valvular Heart Disease by Age 14 Prevalence (%) of Moderate to Severe Valve Disease All valve disease Mitral valve disease Aortic valve disease 0 Age (Years) < >75 11 Page 11

12 Structural Heart Growth Opportunity MitraClip Near-Term Growth Opportunity Addresses significant need in a large, underserved market with a firstin-class technology Continuing to progress in Europe Driving referrals into existing programs; expanding footprint to new centers Launched in U.S. in 4Q13 Improved reimbursement coverage driving further product adoptions 12 Page 12

13 Endovascular: New Opportunity in SFA Acquisition of IDEV Provides Near-Term Growth Opportunity Expands Abbott s peripheral technology portfolio Supera peripheral stent approved by FDA in March 2014 for use in SFA blockages Unique, self-expanding, interwoven wire technology SFA is one of the largest and fastest growing segment of the peripheral stent market ~$500MM market growing ~6-7 percent annually 13 Page 13

14 Diabetes Care Growth Strategies New Technology Expansion and Emerging Market Growth Accelerate growth in key emerging markets Brazil, India, China, Saudi Arabia Capture profitable share in developed markets Shifted focus to insulin-using segment Drive growth through FreeStyle InsuLinx, Precision Neo Transform market Launch next-gen Flash Glucose Monitoring technology On track for 2H14 CE Mark 14 Page 14

15 Vision Care: Cataract Market Growth Global Cataract Market: ~$5Bn Growing 5-6% Annually 80% Incidence of Cataracts With Age 1500 Adults 60+ Globally 70% 60% 50% 40% 30% 20% Millions of People % 0% Page 15

16 Vision Care Growth Strategies New Technology Expansion and Emerging Market Growth Drive above-market growth in cataract with new technologies Tecnis Optiblue Tecnis Toric Preloaded IOL delivery system OptiMedica laser cataract system Accelerate growth in key emerging markets Brazil, India, China Stimulate growth in LASIK business Diagnostic system to deliver superior visual outcomes More space between bullets. 16 Page 16

17 New Opportunity in Laser Cataract Market Acquisition of OptiMedica Provides Near-Term Growth Opportunity Further enhances Abbott s position in cataract market Provides immediate entry point into laser cataract surgery market Laser cataract surgery used in conjunction with premium lenses More space between bullets. 17 Page 17

18 Abbott Medical Devices Aligned with Abbott s Investment Identity Balanced Portfolio Leadership Innovation Emerging Markets Margin Expansion Vascular Diabetes Vision Care #1 DES #1 BVS #1 LASIK #2 Cataract #2 U.S. BGM (retail) Xience Xpedition Absorb MitraClip Supera SFA stent Optiblue; Toric Laser cataract Flash Glucose Monitoring technology 24% of Vascular 17% of ADC 20% of AMO Capturing growth in key markets Opportunities to expand in mid- to longterm with new technology 18 Page 18

19